A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

Conditions:   Sarcoma;   Carcinoma;   Digestive Cancer;   Breast Cancer;   Lung Cancer;   Brain Cancer;   Melanoma;   Gynecologic Cancer;   Head and Neck Cancer;   Kidney Cancer Intervention:   Drug: Recombinant oncolytic herpes simplex virus type 1 (R130) Sponsors:   Shanghai Yunying Medical Technology;   Linyi Central Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials